Sign in to fuzzto save your conversations, follow your research and come back anytime.
Alivus Life Sciences
SectorHealthcare
The Quarter story
The two most recent quarterly results, compared side-by-side.
Alivus Life Sciences expands margins and builds cash reserves as revenue mix shifts toward non-GPL products.
EBITDA margin expands from 30.1% in Q1 FY26 to 36.6% in Q1 FY27, reflecting improved pricing and cost efficiency.
GPL revenue falls from ₹1,526 Cr in Q1 FY26 to ₹723 Cr in Q1 FY27, reducing the contribution from generic products.
Cash reserves grow from ₹6,604 Cr in Q1 FY26 to ₹8,802 Cr in Q1 FY27, strengthening the company's liquidity position.
Free cash flow drops from ₹2,590 Cr in Q4 FY26 to ₹901 Cr in Q1 FY27, indicating higher working capital requirements.
Non-GPL revenue rises from ₹4,492 Cr in Q1 FY26 to ₹5,681 Cr in Q1 FY27, driving the shift in product mix.
Non-GPL share of revenue surges from 74.6% in Q1 FY26 to 88.7% in Q1 FY27, increasing concentration in this segment.
Return on invested capital improves from 28% in Q1 FY26 to 32% in Q1 FY27, showing better returns on deployed capital.
Depreciation and amortization rises from ₹171 Cr in Q1 FY26 to ₹206 Cr in Q1 FY27, reflecting ongoing capacity investments.
Validated products increase from 9 in Q1 FY26 to 13 in Q1 FY27, accelerating the commercial pipeline.
